“These data add to an already robust body of scientific evidence confirming the role of symlin as an important therapeutic option for people living with type 1 diabetes,” said Christian Weyer, M.D., Senior Vice President, Research and Development, Amylin Pharmaceuticals.
New data from two previously completed clinical studies show that Symlin (pramlintide acetate) helped reduce A1c levels, insulin use and body weight in patients with type 1 diabetes who used insulin pumps. The data was presented by Amylin Pharmaceuticals during a poster presentation at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego.
Symlin is a synthetic analog of human amylin, a naturally occurring hormone that is produced and released by beta cells in the pancreas, the same cells that produce and release insulin. In a healthy pancreas, the two hormones work together to help stabilize blood glucose levels. Symlin is approved for use as an adjunct treatment in patients with diabetes who use mealtime insulin therapy (either via insulin injection or insulin pump) and have failed to achieve desired glucose control despite optimal insulin therapy.